GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » Liabilities-to-Assets

Estrella Immunopharma (Estrella Immunopharma) Liabilities-to-Assets : 0.02 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Estrella Immunopharma's Total Liabilities for the quarter that ended in Mar. 2024 was $0.14 Mil. Estrella Immunopharma's Total Assets for the quarter that ended in Mar. 2024 was $8.63 Mil. Therefore, Estrella Immunopharma's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 0.02.


Estrella Immunopharma Liabilities-to-Assets Historical Data

The historical data trend for Estrella Immunopharma's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Liabilities-to-Assets Chart

Estrella Immunopharma Annual Data
Trend Jun21
Liabilities-to-Assets
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.12 - 0.63 0.04 0.02

Competitive Comparison of Estrella Immunopharma's Liabilities-to-Assets

For the Biotechnology subindustry, Estrella Immunopharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Estrella Immunopharma's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's Liabilities-to-Assets falls into.



Estrella Immunopharma Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Estrella Immunopharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2021 is calculated as:

Liabilities-to-Assets (A: Jun. 2021 )=Total Liabilities/Total Assets
=/0
=N/A

Estrella Immunopharma's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=0.138/8.633
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Estrella Immunopharma  (NAS:ESLAW) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Estrella Immunopharma Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines